These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37615111)

  • 21. Vascular inflammation and impaired reverse cholesterol transport and lipid metabolism in obese children and adolescents.
    Martin M; Gaete L; Tetzlaff W; Ferraro F; Lozano Chiappe E; Botta EE; Osta V; Saez MS; Lorenzon Gonzalez MV; Palenque P; Ballerini G; Sorroche P; Boero L; Triffone L; Brites F
    Nutr Metab Cardiovasc Dis; 2022 Jan; 32(1):258-268. PubMed ID: 34895801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipoprotein Particle Profiles, Standard Lipids, and Peripheral Artery Disease Incidence.
    Aday AW; Lawler PR; Cook NR; Ridker PM; Mora S; Pradhan AD
    Circulation; 2018 Nov; 138(21):2330-2341. PubMed ID: 30021845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Large HDL particles negatively associate with leukocyte counts independent of cholesterol efflux capacity: A cross sectional study in the population-based LifeLines DEEP cohort.
    Groenen AG; Bazioti V; van Zeventer IA; Chen L; Groot HE; Balder JW; Zhernakova A; van der Harst P; Rimbert A; Kuivenhoven JA; Fu J; Westerterp M
    Atherosclerosis; 2022 Feb; 343():20-27. PubMed ID: 35091264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-density lipoprotein cholesterol efflux capacity is inversely associated with cardiovascular risk: a systematic review and meta-analysis.
    Qiu C; Zhao X; Zhou Q; Zhang Z
    Lipids Health Dis; 2017 Nov; 16(1):212. PubMed ID: 29126414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic and observational evidence: No independent role for cholesterol efflux over static high-density lipoprotein concentration measures in coronary heart disease risk assessment.
    Kuusisto S; Karjalainen MK; Tillin T; Kangas AJ; Holmes MV; Kähönen M; Lehtimäki T; Viikari J; Perola M; Chaturvedi N; Salomaa V; Raitakari OT; Järvelin MR; Kettunen J; Ala-Korpela M
    J Intern Med; 2022 Jul; 292(1):146-153. PubMed ID: 35289444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of a novel cholesterol efflux assay using immobilized liposome-bound gel beads with the conventional method.
    Horiuchi Y; Lai SJ; Kameda T; Tozuka M; Ohkawa R
    Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32706025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-density lipoprotein cholesterol efflux capacity and cardiovascular risk in autoimmune and non-autoimmune diseases.
    Hafiane A; Favari E; Daskalopoulou SS; Vuilleumier N; Frias MA
    Metabolism; 2020 Mar; 104():154141. PubMed ID: 31923386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of HDL- and non-HDL-related parameters in cell-cholesterol efflux capacity.
    Asztalos BF; Hauser TH; Goldfine AB; Welty FK; Horvath KV; Schaefer EJ
    Atherosclerosis; 2022 Mar; 345():1-6. PubMed ID: 35183903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel association between CDKAL1 and cholesterol efflux capacity: Replication after GWAS-based discovery.
    Cheon EJ; Cha DH; Cho SK; Noh HM; Park S; Kang SM; Gee HY; Lee SH
    Atherosclerosis; 2018 Jun; 273():21-27. PubMed ID: 29674289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatic Cdkal1 deletion regulates HDL catabolism and promotes reverse cholesterol transport.
    An DB; Ann SJ; Seok S; Kang Y; Lee SH
    Atherosclerosis; 2023 Jun; 375():21-29. PubMed ID: 37245423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decreased cholesterol efflux capacity and atherogenic lipid profile in young women with PCOS.
    Roe A; Hillman J; Butts S; Smith M; Rader D; Playford M; Mehta NN; Dokras A
    J Clin Endocrinol Metab; 2014 May; 99(5):E841-7. PubMed ID: 24512495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of transgender hormonal treatment on high density lipoprotein cholesterol efflux capacity.
    van Velzen DM; Adorni MP; Zimetti F; Strazzella A; Simsek S; Sirtori CR; Heijer MD; Ruscica M
    Atherosclerosis; 2021 Apr; 323():44-53. PubMed ID: 33836456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determinants of HDL Cholesterol Efflux Capacity after Virgin Olive Oil Ingestion: Interrelationships with Fluidity of HDL Monolayer.
    Fernández-Castillejo S; Rubió L; Hernáez Á; Catalán Ú; Pedret A; Valls RM; Mosele JI; Covas MI; Remaley AT; Castañer O; Motilva MJ; Solá R
    Mol Nutr Food Res; 2017 Dec; 61(12):. PubMed ID: 28887843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adiponectin Predicts High-Density Lipoprotein Cholesterol Efflux Capacity in Adults Irrespective of Body Mass Index and Fat Distribution.
    Marsche G; Zelzer S; Meinitzer A; Kern S; Meissl S; Pregartner G; Weghuber D; Almer G; Mangge H
    J Clin Endocrinol Metab; 2017 Nov; 102(11):4117-4123. PubMed ID: 28938424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The association between impairment of HDL cholesterol efflux capacity and atrial remodeling in atrial fibrillation.
    Minami-Takano A; Iwata H; Miyosawa K; Shiozawa T; Hayashi H; Funamizu T; Ishii K; Nozaki Y; Tabuchi H; Sekita G; Shimada K; Sumiyoshi M; Nakazato Y; Daida H; Minamino T
    Sci Rep; 2021 Feb; 11(1):3547. PubMed ID: 33574408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives.
    Adorni MP; Ronda N; Bernini F; Zimetti F
    Cells; 2021 Mar; 10(3):. PubMed ID: 33807918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-density lipoprotein remodeling by phospholipid nanoparticles improves cholesterol efflux capacity and protects from atherosclerosis.
    Kudinov VA; Torkhovskaya TI; Zakharova TS; Morozevich GE; Artyushev RI; Zubareva MY; Markin SS
    Biomed Pharmacother; 2021 Sep; 141():111900. PubMed ID: 34328100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of pre-eclampsia on HDL-mediated cholesterol efflux capacity after pregnancy.
    Kockx M; Roberts L; Wang J; Tran C; Brown MA; Kritharides L
    Atheroscler Plus; 2022 Apr; 48():12-19. PubMed ID: 36644562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cholesterol efflux capacity of high-density lipoprotein was not associated with cognitive decline and brain structures in older people with diabetes mellitus.
    Wu Y; Tan KC; Shiu SW; Luo Y; Shi L; Kwok TC
    J Diabetes Investig; 2022 Nov; 13(11):1873-1880. PubMed ID: 35731136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.